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Abundant research has mapped the inﬂammatory pathways leading to autoimmunity and neuroinﬂammatory disorders. The
latest T helper to be identiﬁed, Th17, through its proinﬂammatory cytokine IL-17, plays a pathogenic role in many inﬂammatory
conditions. Today, healthcare providers have a wealth of anti-inﬂammatory agents from which to choose. On one hand,
pharmaceutical companies market brand-name drugs direct to the public and physicians. Medical botanical knowledge, on the
other hand, has been passed down from generation to generation. The demands for natural healing therapies have brought
corresponding clinical and laboratory research studies to elucidate the medicinal properties of alternative practices. With a
variety of options, it can be diﬃcult to pinpoint the proper anti-inﬂammatory agent for each case presented. In this review, the
authors highlight a vast array of anti-inﬂammatory medicaments ranging from drugs to vitamins and from botanicals to innate
molecules. This compilation may serve as a guide for complimentary and alternative healthcare providers who need to target
neuroinﬂammation driven by Th17 and its inﬂammatory cytokine IL-17. By understanding the mechanisms of anti-inﬂammatory
agents, CAM practitioners can tailor therapeutic interventions to ﬁt the needs of the patient, thereby providing faster relief from
inﬂammatory complaints.
1.Introduction
Parts I and II of this series detail the destructive Th17
inﬂammatory pathway. Here, we present ways to intervene.
The absence of Th17 cells can lead to a decrease in
proinﬂammatory cytokines. Thus, to achieve the end goal of
a balanced immune response, CAM practitioners may target
components along the pathway leading from na¨ ıve T-cell
diﬀerentiation to Th17, thereby lowering the levels of Th17
and IL-17. Treatment may include enhancing immunity by
administering an agonist, or depressing Th17 cell function
by introducing an antagonist of RORγt. The CAM protocol
of RORγt agonist therapy may be applied to cancer patients
when up-regulation of the immune response is needed.
Intervention in autoimmune disorders or neurodegenerative
diseases such as irritable bowel disorder, arthritis, diabetes
and multiple sclerosis may include the use of antagonists to
RORγt. Current methods, outlined here, include a choice of
medicines ranging from pharmaceuticals to the integrative
practice of intravenous therapy, and from natural plant
extracts to innate molecules. Whether mainstream or alter-
native in practice, sometimes the most eﬀective intervention
includes a combination of these anti-inﬂammatory agents
that is suitable for CAM.
2.TargetingTh17, RORγt Using Medications
andPharmaceuticals
General, or speciﬁc, medications have been or are being
developed to reduce the symptoms of inﬂammatory diseases.
Neuroprotective medications currently used for blocking
microglial activation include minocycline or dextromethor-
phan [1]. The anti-inﬂammatory mechanisms of minocy-
cline [2, 3] and dextromethorphan [4, 5] are unknown
at this time; however, these products have been shown
to be eﬀective against neuroinﬂammation. An antibiotic
that inhibits the response to IL-2 and thereby blocks the
activation of both T cells and B cells, rapamycin, now called
sirolimus, is used to combat autoimmunity and to prevent
acute graft rejection [6]. To protect intestinal microﬂora and
prevent further inﬂammatory damage, the use of antibiotics
must be used in conjunction with a probiotic program.
Medications are not always favored; some practitioners
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with chronic inﬂammatory disorders. Insulin-like growth
factor-1 (IGF-1) is principally produced by the liver and
circulatesintheblood.Decreasingwithage,alackofIGF-1is
found in degenerative arthritis, septic shock, cardiovascular
disease and inﬂammation of the bowel [7]. Treatment
with intravenous immunoglobulin (IVIG), a plasma protein
replacement therapy, uses immunoglobulins extracted from
multiple healthy blood donors, is in use to decrease the
severity of autoimmune disease [8, 9]. However, since IGF-1
t r e a t m e n tm a yi n c r e a s eg r o w t hh o r m o n ea n dg r o w t hf a c t o r ,
this should be the last choice [10].
The use of anti-cytokine treatments that target inﬂam-
mation in autoimmune disorders is gaining popularity.
Recombinant soluble TNF receptor, etanercept (Enbrel),
binds to TNF and blocks inﬂammatory activity, while
inﬂiximab (Remicade) and adalimumab (Humira) are mon-
oclonal antibodies speciﬁc for TNF, thus also binding to
TNF and blocking inﬂammatory activity [11–14]. These
anti-cytokine therapies are not speciﬁc and their long-term
use can result in the development of immune complexes
[15]. Pharmaceutical reviews by Drugs.com, an independent
Internetsourceforconsumersandhealthcareproviders,oﬀer
warnings associated with anti-cytokine medications that
include drug interactions, suppressed immunity, exacerba-
tion of heart disease and susceptibility to serious infections.
These are just a few examples from a laundry list of potential
problems. Full investigation into drug interactions, side
eﬀectsandpossibledireconsequencesoflong-termuseneeds
to be performed before the onset of pharmaceutical, anti-
cytokine treatment.
3.TargetingTh17 throughtheRORγtP a t h w a y
Possible targets for the suppression of Th17 production
include four components: RORγt, TGF-β,I L - 6a n dN F - κB.
Inhibition of NF-κB promotes the production of proinﬂam-
matory cytokines and can result in an improved balance
between pro- and anti-inﬂammatory cytokines. Inhibiting
IL-6 production, which is required for the induction of
RORγt, may result in the inhibition of Th17 and the
production of IL-17 cytokines. Enhancing the production of
TGF-β, as this cytokine can inﬂuence transcription FoxP3,
can diﬀerentiate the T cell into a regulatory T cell (Treg).
Therefore, down-regulating RORγt, the transcription factor
responsible for T-cell diﬀerentiation to Th17, will result in
the reduction of the number of Th17 cells and therefore
theircytokines.Overall,manipulationofthepathwaytoward
the production of IL-17 can result in the inhibition of an
inﬂammatory cascade.
3.1. Targeting RORγt. Retinoic acid-related orphan receptor
(ROR)γt is the key that unlocks the diﬀerentiation of na¨ ıve
T-cells to eﬀector Th17 cells. RORγt is expressed exclu-
sively by immune system cells, double positive CD4+CD8+
thymocytes [16]. Interestingly, both IL-6 and TGF-β are
individually capable of expressing small amounts of RORγt;
however, neither can singly induce IL-17-secreting Th17.
According to Batten et al. [17], the over-expression of this
transcription factor induces production of Th17 and its
eﬀector cytokine IL-17; conversely, a deﬁciency of RORγt
nearly halts T-cell diﬀerentiation to Th17. Therefore, by
eliminating the key that unlocks IL-17-expressing Th17
cells, CAM practitioners may turn around the inﬂammatory
responsebytargetingRORγtcellsintheirpatientspresenting
with neuroimmune inﬂammatory disorders.
High levels of RORγt are present in inﬂammatory dis-
eases, autoimmune disorders and food allergies. Treatment
of immune-mediated diseases characterized by the presence
of inﬂammatory cytokines, such as inﬂammatory bowel
diseases, multiple sclerosis, arthritis, dry eye autoimmune
disease and diabetes, may involve RORγt antagonists, while
administration of agonists to RORγt may be helpful in
the treatment of infectious diseases and boosting anti-
tumor immunity [16, 18]. By the enhancement of mucosal
immunity or the increase in the number of T cells reactive
to a speciﬁc antigen, RORγt-developed Th17 can protect the
host from infection.
The proximity of RORγt to Th17 in the development
of IL-17 makes it a pivotal step in the immune response.
When Th17 protection is necessary, the up-regulation of
RORγt would be beneﬁcial. On the other hand, if chronic
inﬂammation exists, the production of IL-17 should be
minimized, and thus the suppression of RORγt is desirable.
4.TargetingTh17, RORγtU s in g
Complimentary andAlternativeAgents
Due to risks associated with long-term use, undesirable side
eﬀects and the ineﬀectiveness of healing properties exhibited
by many pharmaceutical agents, more and more patients
suﬀering from chronic inﬂammatory disorders are turning
to complementary and alternative medicine therapies. CAM
practitioners have a wealth of natural alternatives to reduce
inﬂammation. Previous authors of articles from Evidence-
Based Complimentary and Alternative Medicine and other
journals have provided an excellent insight into anti-
inﬂammatories,suchasMoutanCortex(rootbarkofPaeonia
suﬀruticosa Andrews) featured by Chun et al. [19]a n d
l a t e rb yW ua n dG u[ 20]; Perillae fructus (perilla seed) by
Yim et al. [21], atractylenolide I (extracted from largehead
atractylodes rhizome)b yL i ue ta l .[ 22], and Chen et al. [23]
examination of Tibetan medicated-bath therapy. Additional
published natural anti-inﬂammatories that have been shown
to inhibit the production of proinﬂammatory cytokines
include Opuntia humifusa Raf. [24], total ﬂavonoids of
Fructus Chorspondiatis [25], Artemisia annua L. [26], Kum-
merowia striata (Thunb.) Schindl [27] and a mini review of
plant extracts by Talhouk et al. [28] focusing on the anti-
inﬂammatory properties of bioﬂavonoids (Table 1).
Indeed, the antioxidant activity and inﬂammatory
response of ﬂavonoids, or bioﬂavonoids, are of interest due
to their therapeutic uses as anti-allergic, anti-cancer activity,
anti-microbial and anti-inﬂammatory in the prevention
or maintenance of various disorders. Natural antioxidants
remove damaging free radicals and inhibit other oxidation
reactions. By using diﬀerent routes during inﬂammatory
responses, ﬂavonoids are able to block a range of known
molecules, notably NF-κB, inducible nitric oxide synthaseEvidence-Based Complementary and Alternative Medicine 3
Table 1: Natural alternatives for reducing inﬂammation in autoimmune conditions.
Agent Reference Result
Moutan cortex [19] Reduced concentration of TNF-α,I L - 1 β and IL-6 in LPS-stimulated
RAW264.7 cells
Moutan cortex [20] Increased production of IL-10 and a decrease in level of proinﬂammatory
cytokines
Perillae Fructus [21] Suppressed IL-4 production, inhibiting IgE secretion; reduced IL-5 and IL-13;
suppressed excess Th2 activity and rebalanced Th1/Th2
Atractylenolide I [22] Up-regulate TNF; down-regulate IL-1
Tibetan medicated-bath [23] Decreased IL-6 and TNF-α levels
Opuntia humifusa Raf [24] Blocked expression of IL-6 from LPS-stimulated RAW264.7 cells
Total Flavonoids of Fructus
Chorspondiatis
[25] Inhibited NF-κB signaling pathway
Artemisia annua L. [26] Inhibited IL-17A production; reduced mRNA expression of RORγt; reduced
IL-6 production
Kummerowia striata (Thunb.)
Schindl ethanol extract
[27] Suppressed NF-κB activation; up-regulated IL-10 and HO-1
Artemisia alba [28] Inhibited IL-1-induced NF-κB and AP-1 activation
Ginger extract from Alpinia gallanga
and Zingiber oﬃcinale
[28] Reduced level of mRNA
Longicera japonica [28] Inhibited LPS-induced degradation of I-κBα and induction of NF-κB p65,
TNF-α and inducible NO synthase (iNOS)
Phlebodium decumanum [28] Reduced TNF production; inhibited IL-6 production; increased release of
TNF-R2 and IL-1 receptor agonist
Scandix austalis extracts [28] Inhibited IL-1-induced NF-κB and AP-1 activation
Tripterygium wilfordii [28] Lowered the inﬂammatory response
Urtica dioica leaf extracts [28] Inhibited NF-κB
(iNOS), cooxygenase (COX) and 5 lipoxygenase enzymes,
resulting in the down-regulation of inﬂammatory cytokines
such as IL-1β,I L - 6a n dT N F - α.
The list of published studies elucidating CAM therapeu-
tic results against inﬂammatory responses is enormous. In
the interest of space, we will conﬁne our review to well-
documented, natural substances that have been demon-
strated to modulate Th17 or IL-17 as they are implicated in
many neuroimmune, autoimmune and allergic disorders.
4.1. Targeting Th17, RORγt, Using Retinoic Acid, Vitamin
D3, Resveratrol and Probiotics. Retinoic acid, the oxidized
form of vitamin A, has long been viewed as important to
both the innate and the acquired immune systems. The
transcription factor RORγt, which if overexpressed, induces
T-cell diﬀerentiation to Th17, belongs to a retinoid nuclear
receptor superfamily [17]. Kim [29]p r o v i d e sa ne x c e l l e n t
review of published research data referencing the regulation
of regulatory T cells by retinoids. Recently, researchers have
recognized retinoic acid’s regulation in immune responses
[17, 30]. It was shown to suppress memory cell IFN-γ pro-
duction and increase IL-4 secretion [17]. Mucida et al. [30]
completed a study that measured the eﬀect of retinoic acid
on Th17 cell development both in vitro and in vivo.I ne a c h
case, retinoic acid greatly reduced RORγt expression, which
resulted in a measurable reduction of Th17 mucosal T cells.
Further, all-trans retinoic acid (ATRA) has been reported to
inhibit Th17 production and to promote FoxP3 expression,
thereby aﬀecting the Th17/Treg polarization [17]. Retinoic
acid’s importance to the immune system cannot overshadow
its promotion of glial and neuronal diﬀerentiation. Within
the CNS (central nervous system), retinoic acid has been
shown to enhance axonal regeneration of diﬀerentiated
retinal ganglion cells and peripheral sensory neurons [31].
Therefore,supplementationwithlowdosesofvitaminAmay
be useful for treatment of neuroimmune disorders.
4.2. 1α,25-Dihydroxyvitamin D3. T h ea c t i v em e t a b o l i t eo f
vitamin D3,1 α,25-dihydroxyvitamin D3 (1,25(OH)2D3),
which can prevent the maturation of dendritic cells resulting
in tolerogenic dendritic cells with increased potential to
induce regulatory T cells is a proven potent inhibitor of NF-
κB expression. Taher et al. [32], using a mouse model of
allergic asthma, demonstrated that the 1,25(OH)2D3 aug-
mentation of immunotherapy resulted in increased serum
levels of TGF-β, and thus prevented the Th2-driven devel-
opment of asthma manifestations. In a study comprising
patients with multiple sclerosis, researchers saw a rise in
TGF-β levels following a 6-month supplementation phase
of vitamin D [33]. Interestingly, there were no changes in
TNF-α,I F N - γ and IL-13 levels. Vitamin D3 acts by binding
in signal transduction pathways such as the regulation
of intracellular concentrations, protein kinase C activity,
phospholipids metabolism and cyclic nucleotide formation4 Evidence-Based Complementary and Alternative Medicine
[33]. CAM practitioners, by speciﬁcally targeting an increase
of TGF-β, should consider the eﬀectiveness of vitamin D3,
as it has been shown to reduce autoimmune incidences of
cardiovascular disease [34], diabetes [35, 36], rheumatoid
arthritis [37, 38] and lupus [39].
4.3. Resveratrol. A phytoalexin produced by several plants
when under bacterial or fungal attack; resveratrol has
become a popular supplement due to the French paradox.
It has been suggested that the resveratrol found in the
skin of red grapes explains the low incidence of cardio-
vascular disease in France where wine is consumed almost
daily [40]. Indeed, immunostimulant resveratrol has been
demonstrated to exhibit antioxidant properties and anti-
inﬂammatory characteristics; it stimulates natural killer cell
activityandexercisesanti-tumorpropertiesthroughthesup-
pression of the NF-κB signaling pathway [41]. Gonzales and
Orlando [42] studied the eﬀects of resveratrol and curcumin
on the NF-κB-mediated cytokine expression in adipocytes.
They concluded that both supplements were able to inhibit
TNF-α-activated NF-κB signaling in adipocytes and thereby
reduced TNF-α,I L - 1 β and IL-6 cytokine expressions. The
authors of this study suggest the potential use of resveratrol
and curcumin in the development of therapeutic protocols
aimed at alleviating the low-level, chronic inﬂammation
often seen in obese patients with a propensity toward
cardiovascular disorders and insulin resistance associated
withtype2diabetesmellitus.Incasesofneuroinﬂammation,
the small molecules of resveratrol can easily pass through
the blood-brain barrier where they are shown to be neuron-
protective. Resveratrol stimulates the production of nicoti-
namide adenine dinucleotide (NAD), and therefore, is used
toslowtheprogressofamyotrophiclateralsclerosis[43].The
neuroimmune protective characteristics of resveratrol make
it an attractive and versatile option for CAM practitioners.
4.4. Non-Pathogenic Probiotic Bacteria. The human gut is a
hometoavastconsortiumofsymbioticbacteria.Membersof
this complex microﬂora metabolize dietary substances, such
as plant polysaccharides, that are otherwise indigestible by
their human hosts. Interest in the gut ﬂora has led to numer-
ous investigations to demonstrate that there are beneﬁcial
and potentially harmful microorganisms in the intestine,
and that the one could be used to inﬂuence the activities
of the other. These ﬁndings led to the “probiotic” concept,
originally used to describe microbial feed supplements that
stimulate the growth of farm animals. Now, the use of
live microbes as dietary supplements has been extended to
humans [44]. The genera most commonly used in probiotic
preparationsareLactobacillus,Biﬁdobacterium,Streptococcus,
Lactococcus and some fungal strains.
Some of the health beneﬁts which have been claimed for
probiotics include the following: improvement of the nor-
mal microﬂora, prevention of infectious diseases and food
allergies, reduction of serum cholesterol, anticarcinogenic
activity, stabilization of the gut mucosal barrier, immune
adjuvant properties, alleviation of intestinal bowel disease
symptoms and improvement in the digestion of lactose in
intolerant hosts. The beneﬁcial eﬀects of probiotic bacteria
Table 2: Some individual bacterial strains that inﬂuence the
immune system [47].
Strain Eﬀect
L. casei Shirota Induced IL-12 production
Heat-killed L. casei and L.
fermentum Induced TNF-α production
L. paracasei Ncc2461 Induced CD4+ T-cells to produce
IL-10 and TGF-β
L. rhamnosus GG with LPS Inhibited TNF-α,b u tn o tI L - 1 0
L. reuteri + L. brevis Induced TNF-α,I L - 2 ,I L - 1 β
L. rhamnasus + L.
acidophilus + B. lactic
Enhanced immunoreactivity of
spleen cells and phagocytes
L. acidophilis + L.
delbrueckii ssp bulgaricus +
B. biﬁdum
Produced an anti-inﬂammatory
response
L. casei Shirota Inhibited translocation of NF-κB
and production of IL-6
L., Lactobacillus; B., Biﬁdobacterium.
in relation to the augmentation of the immune system and
cytokine production were summarized in a mini review by
Galdeano et al. [44]. Pochard et al. [45] experimented with
lactic acid bacteria and concluded that its administration
enhanced the secretion of IL-12 and IFN-γ, thereby mod-
ulating the Th1/Th2 balance in cases of allergy. M´ enard et
al. [46] determined that metabolites secreted by lactic acid
bacteria exerted an anti-TNF-α eﬀect capable of crossing
the intestinal barrier, and showed that LPS binding to Th1
cells and NF-κB was signiﬁcantly inhibited. Administration
of lactic acid bacteria in prebiotic and probiotic forms can
now be tailored to the needs of the patient. The inﬂuence on
the immune system of individual bacterial strains has been
conveniently compiled by Ljungh and Wadstr¨ om [47]. An
abbreviated listing is shown in Table 2. Lactic acid used in
combination with Saccharomyces boulardii,ay e a s tf o u n do n
lychee fruit, which has proven to be eﬀective in preventing
diarrhea and rdecreasing toxin A and toxin B, provides
protection [48]. With this information, CAM practitioners
may select lactic acid bacteria with Saccharomyces boularddii
toenhanceTGF-β-bearingregulatorycellsandinhibitproin-
ﬂammatory cytokine production. Therefore, Lactobacillus,
other probiotic bacteria and their antigens may have a
promise as new therapeutic agents for the treatment of
many neuroimmune disorders that start in the GI tract and
manifest in the nervous system.
4.5. Targeting NF-κB. Part II of this series details the
pathophysiology of intestinal epithelial tight junction per-
meability leading to the disruption of blood-brain bar-
riers by Th17 cells, resulting in neuroinﬂammation. In
this scenario, nuclear transcription factor kappa B (NF-
κB) is a powerful instigator of inﬂammation. Therefore,
targeting NF-κB may dampen neuroinﬂammation induced
by Th17. Target genes of NF-κB may be divided into
diﬀerentfunctionalgroupstorevealapredominanceofthose
with primarily inﬂammatory functions. Kempe et al. [49]Evidence-Based Complementary and Alternative Medicine 5
classiﬁed NF-κB target genes and found that genes for
monocyte,macrophage,neutrophilsandT-cellchemoattrac-
tant chemokines and cytokines (RANTES, CCL20, CXCL3,
CXCL2, CXCL11, CXCL6, MCP-1, IL-8 and GM-CSF) were
up-regulated. Through the mitogen-activated protein kinase
(MAPK) pathway, the phosphorylation and degradation of
the NF-κB-speciﬁc cytoplasmic inhibitor IκBα and subse-
quent activation and nuclear translocation of NF-κBi ss e t
in motion [50]. The initiation of NF-κB activation occurs via
cytokine signaling, innate or adaptive immune responses or
environmental stressors. NF-κB’s key role is the regulation of
immuneresponsestoviralantigensortobacterialantigensas
is implicated in the opening of intestinal tight junctions [51,
52]. Activation of NF-κB indicates down-stream interplay
between the hypothalamic-pituitary-adrenal (HPA) axis and
sympathetic nerve terminals as the endocrine response to
psychological stressors and contributes to changes in the
activity of the neuroendocrine axis to cellular behavior [49,
50].
Once the intersected activation pathways of NF-κBa r e
stimulated, an increase in certain proinﬂammatory cytokine
levels is evident. This may involve TNF-α,I L - 1 β [51], IL-
6[ 53] and IL-8 [49, 52, 53]. Infections elicit the inﬂam-
matory response of IL-1β, which aﬀects an increase in the
expression of adhesion factors on endothelial cells to allow
the transmigration of pathogen-ﬁghting leukocytes to sites
of infection. IL-1β is implicated in rheumatoid arthritis (RA)
and enhanced intestinal permeability [51, 52]. Proinﬂamma-
tory and anti-inﬂammatory IL-6 is detected in Castelman’s
disease, chronic lymphadenitis, Basedow’s disease, Sj¨ ogren’s
syndrome and RA [54] .S e c r e t e db ya n yc e l l sw i t ht o l l -
like receptors involved in the innate immune response, IL-8
functions to recruit neutrophils to phagocytose the antigen.
High levels of IL-8 in pregnant women indicate a higher
risk of inducing schizophrenia in oﬀspring [55]. Each of
these cytokines, IL-1β, IL-6, IL-8 and TNF-α, is capable of
promoting the progression of inﬂammatory, autoimmune or
neuroinﬂammatory disorders [51–55].
A multitude of complementary, and alternative, medici-
nal extracts aﬀecting NF-κB have been studied. Recent pub-
lications focusing on antioxidants to inhibit the activation
of NF-κB include aged garlic extract (allicin) [56], beta-
carotene [57], curcumin [58]a n dq u e r c e t i n[ 59]. Jiang et
al. [60] concluded that lyceum seed oil is able to inhibit
NF-κB through the modulation of NF-κB expression; while
Rajakangas’ group [61] studied nuclear translocation and
found white currant to be an eﬀective agent that inhibits NF-
κB. This transcription factor plays key roles in a variety of
cellularprocessesrangingfrominﬂammationtocancer,from
diﬀerentiation to apoptosis and from immune response to
proliferation.Acetyl-boswellicacidswereusedinastudy[62]
to show that in LPS-stimulated human peripheral mono-
cytes, these molecules down-regulated TNF-α expression
through the inhibition of NF-κB. These ﬁnding suggest
acetyl-boswellic acids as a tool for the development of novel
therapeutic interventions. Therefore, the modulation of NF-
κB and associated cytokines such as IL-1β,I L 6 ,I L - 8a n d
TNF-α by using one or a combination of diﬀerent herbal
medicines may suppress Th17 and IL-17 production and
inhibit neuroinﬂammation. CAM practitioners may thus
consider NF-κB modulation for therapeutic intervention or
maintenance of neuroimmune inﬂammatory disorders.
4.6. Targeting TGF-β. A pleiotropic cytokine secreted by
many cells, TGF-1β, plays vital neuroimmune roles. It
can control cell growth, diﬀerentiation, inﬂammation, cell
chemotaxis, apoptosis, hematopoiesis and plays a role in
the protection of neurons from cell death induced by gluta-
mate excitotoxic chemical hypoxia, apoptosis and oxidative
injury [63]. Like its partner in the Th17 diﬀerentiation
pathway, TGF-1β possesses bipolar characteristics. It is both
a neuroprotective factor and a trigger of neuronal cell
death [63]. This anti-inﬂammatory cytokine assists in T-
cell diﬀerentiation. Under conditions of high concentration
of TGF-β, which induces the expression of FoxP3, the
na¨ ıve T-cell has been shown to diﬀerentiate into anti-
inﬂammatory Treg, while in the presence of low levels, it
will diﬀerentiate to proinﬂammatory Th17 [64–66]. Thus,
by increasing the level of TGF-β, CAM practitioners may
aﬀect T-cell diﬀerentiation by polarizing the Th17/Treg ratio
toward anti-inﬂammatory Treg forcasesofinﬂammationand
autoimmunity.
4.7. Targeting IL-6. Considered both pro- and anti-
inﬂammatory, IL-6 plays a dual role. When secreted by
T-cells and macrophages, IL-6 stimulates immune responses
to trauma such as burns and tissue damage, and during
bouts of exercise, muscle tissue cells will produce IL-6
[68]. Additionally, IL-6 can be produced by endothelial
cells, retinal pigment epithelial cells, some tumor cells,
astrocytes, ﬁbroblasts, keratinocytes, bone marrow stromal
c e l l sa n da c t i v a t e dTa n dBc e l l s[ 69–75]. In the presence
of IL-6, low concentrations of TGF-β induce the expression
of RORγt resulting in diﬀerentiation to Th17 and thus
the secretion of volatile IL-17. Because of its inhibitory
eﬀects on TNF-α and IL-1 and activation of its interleukin-1
receptor agonist (IL-1RA) and IL-10, IL-6 can be deﬁned as
anti-inﬂammatory. Due to this duplicity, targeting IL-6 can
be tricky. A balance of IL-6 is necessary to keep the level of
Th17 cells down, while at the same time inhibiting TNF-α
and IL-1. The use of bioﬂavonoids, previously described
a n ds u m m a r i z e di nTable 1, to block NF-κB resulting in
the down-regulation of IL-6 can bring down the cytokines
involved in the inﬂammatory response [56–61].
4.8. Targeting Th17, RORγt Using Other Molecules. Innate
agents that merit targeting include somatostatin and kynure-
nine with norepinephrine (NE). Naturally occurring in
the body, somatostatin in gastrointestinal mucosa and
kynurenines and NE in the nervous system, together these
molecules play regulatory roles in inﬂammatory responses.
The mucosal layer of the gastrointestinal tract is the body’s
ﬁrst line of defense against environmental stressors. It
is somatostatin’s ability to reduce inﬂammation [76–78],
which helps to keep the intestinal barrier functioning in
its protective role. For this reason, CAM researchers may
target somatostatin and kynurenine using tryptophan and
hydroxytryptophan for down-regulation of neuroimmune6 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Degradation of tryptophan through the Kynurenine pathway by indolamine 2, 3 dioxygenase and its activation by highly inducible
proinﬂammatory cytokines. Modiﬁed from Conklin et al. [67].
disorders. Through meticulous studies [79, 80], researchers
have elucidated the arduous pathways, both protective and
toxic, of kynurenines and have found that by inhibiting the
kynurenine pathway, brain damage from cerebral inﬂam-
mation is reduced in animal models (see Figure 1). Natural
molecules may be favored in some therapeutic interven-
tions; however, targeting kynurenines, without upsetting the
multiple neurotransmitter pathways they aﬀect, can be very
complicated.
4.9. Targeting Somatostatin. As regulatory hormone, soma-
tostatinisexpressedinthegastrointestinaltract(wherenerve
endings deliver somatostatin to the epithelial cells), pancreas
and regions of the CNS. Classiﬁed as an inhibitory hormone,
ithasbeenshowntoimpedeproinﬂammatoryresponses[81,
82]. Of particular interest, somatostatin secreted from non-
neuronal cells along the digestive tract plays an important
role as a mediator during mucosal inﬂammatory responses
after physiological (induced by TNF-α) and pathophysiolog-
ical (up-regulation of bacteria) stimulations [77]. Chowers
et al. [77] found that somatostatin eﬀectively inhibited
spontaneously secreted IL-8 and IL-1β,a sw e l la ss e c r e t i o n
initiated by TNF-α or bacterial invasion stimulation. More
recently, Zavros et al. [78] concluded that circulating levels
of somatostatin increased by infusion of IL-4, while IFN-
γ suppressed the D-cell release of this peptide during
inﬂammation; thus, Th1 predominant gastritis may be
quelled through the up-regulation of somatostatin. Through
reduced inﬂammation, the immunoregulatory function of
somatostatin in the gastrointestinal tract may prevent the
possibility of neurodegeneration that can occur after chronic
intestinal barrier dysfunction.
Products of activated immune cells may exert their
inﬂuence over the nervous system either by active transport
of circulating cytokines into the CNS or via cytokine
receptors located on the vagal nerve [83]. A key modulator
of the sympathetic nervous system is the neurotransmitter
norepinephrine (NE). Various levels of this neurotransmit-
ter play an important role in anti- and proinﬂammatory
biological responses. Increased NE, acting centrally, can
contribute to the release of anti-inﬂammatory cytokines,
whereas low concentrations support a proinﬂammatory
biological state [84, 85]. Therefore, it has become crucial to
determine neurotransmitter levels, as sub-optimal quantities
favor potentially damaging proinﬂammatory activities. Con-
siderable evidence has given credence to the important role
of NE in manipulating adaptive immunity [86]. In a study
involving mice, NE was required for the production of a Th1
cell-mediatedimmuneresponseandperhapsfurtheraﬀected
the development of Th1 [87]. Additionally, it has been
proposed that NE is important in increasing the magnitude
of a Th1 immune reaction [88]. Altogether, these studies
indicate that NE may enhance the eventual production
of Th1 cells [83]. Many studies have implicated IL-6 in
contributing a key dose-dependent role in sympathetic nerve
activity. Speciﬁcally, the combined concentrations of sub-
threshold IL-6 and IL-1β can attenuate sympathetic nerve
activity [83]. Under stress-induced situations, where optimal
NE levels were present, NE attenuated the release of TNF-α
along with IL-6 [86]. Taken together not only can IL-6 and
TNF-α augment, attenuate or silence in their eﬀects on rate
of release of NE [89], but it is decisively clear that NE itself
can signiﬁcantly inﬂuence whether a system is more prone to
anti- or proinﬂammatory responses.
NE is responsible for most of the activity within the
sympathetic nervous system. It mediates the inhibition of T-
and B-cell activations, inhibits IL-2-generated lymphocyte
activation and modulates keratinocyte mitogenesis [86, 90,
91]. Low levels of NE promote a proinﬂammatory state,
while the up-regulation of NE favors anti-inﬂammatory
cytokines [92]. Interestingly, all kynurenines and resultant
intermediates can be measured in blood and urine [79];Evidence-Based Complementary and Alternative Medicine 7
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Figure 2: Various CAM intervention methods with appropriate references for targeting TH17 RORγt cells in autoimmune disorders or
neurodegenerative diseases are shown. Possibilities range from pharmaceuticals to natural plant extracts and innate molecules.
therefore, targeting kynurenines in conjunction with NE
measurements will provide an invaluable therapeutic advan-
tage for healthcare practitioners to achieve the best patient
results. In patients with neuroinﬂammation and autoimmu-
nity, these intervention methods for targeting Th17 RORγt
cellsrangingfrompharmaceuticaltoplantextractsandother
molecules with appropriate references are shown in Figure 2.
5. Conclusion
During the past 30 years, discussions about the limitations
of Th1/Th2 implications for health and disease have resulted
in several major revisions of the hypothesis, and hence,
the identiﬁcation of Treg and Th17 cells. Currently, these
subsets of CD4+ T-helper cells are classiﬁed based upon
unique cytokine products, signaling pathways and lineage-
speciﬁc transcription factors. However, recent data argue
for more complexity and ﬂexibility in these subsets than
was previously assumed [93]. As with any model, ﬂexibility
and plasticity of the T-cell subset are the subject of intense
investigation and enhancement. As was concluded by Wilson
et al. [94], “a future challenge will be to determine with
greater clarity how speciﬁc combinations of epigenetic mod-
iﬁcations are established by networks of lineage-specifying
transcription factors, and whether, when and how they can
later be removed or selectively modiﬁed to achieve or alter
TH-lineage speciﬁcation”.
Thus, based on the best available evidence, the modi-
ﬁcation of TH-lineage requires a full understanding of the
neuroimmune inﬂammatory pathway, which is necessary to
combat inﬂammation, autoimmunity and neurodegenera-
tion. In this regard it is vital to understand the signiﬁcant
roles played in neuroinﬂammation by Th17 and its eﬀector
cytokine, IL-17, in conjunction with IL-23, IL-27 and Th1
autoreactive cells.
Although IL-17 is highly pathogenic, as evidenced by its
presence in a variety of inﬂammatory disorders, its initial
intent is not destructive. Th17 plays a protective role in host
defense against infection, by inducing chemokine and G-
CSF expression from surrounding cells thereby recruiting
neutrophils and macrophages to infected tissues [16, 95].
Within the intestinal mucosa, naturally occurring Th17
cells control a variety of bacterial and fungal infections
at the mucosal surfaces [95–98]. It is in the presence of
chronic inﬂammation that Th17 becomes destructive and
over produces IL-17 [98, 99].
Through careful manipulation of the RORγtd i ﬀeren-
tiation of na¨ ıve T cells into the Th17 cells cascade using
the diﬀerent CAM modalities described in this manuscript,
a balanced immune response can be achieved. Research8 Evidence-Based Complementary and Alternative Medicine
and technology have deﬁned diverse therapeutic options,
which have been mentioned above. With a variety of choices
available,therapycanbetailoredtoﬁttheindividualpatient’s
needs. Whether using pharmaceutical or natural treatments,
itisimportanttoestablishthepatient’sleveloftissue-speciﬁc
antibodies, status of immune function, including cytokine
production before commencing therapy. Such laboratory
assessments should be repeated periodically to monitor the
eﬀectiveness of the treatment protocol. Alterations may
be required to recover from the inﬂammation inherent in
autoimmune, neuroimmune and neurodegenerative diseases
and return to a state of optimal health. More research and
publications are needed before a proper meta-analysis of
compiled data can be professionally assessed. However, the
small number of studies presented in this manuscript shows
encouraging experimental evidence, which may inspire the
execution of larger, longitudinal research projects in the
near future. This additional information could yield detailed
cross-comparisons of integrative and CAM therapies for
inﬂammatory and autoimmune disorders.
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